Skeletal muscle alterations in HFrEF vs. HFpEF

被引:43
作者
Adams V. [1 ]
Linke A. [1 ]
Winzer E. [1 ]
机构
[1] Clinic of Cardiology, Heart Center Leipzig, Strümpellstrasse 39, Leipzig
关键词
Heart failure; Heart failure with preserved ejection fraction; Heart failure with reduced ejection fraction; Skeletal muscle;
D O I
10.1007/s11897-017-0361-9
中图分类号
学科分类号
摘要
Purpose of review: Severe exercise intolerance and early fatigue are hallmarks of heart failure patients either with a reduced (HFrEF) or a still preserved (HFpEF) ejection fraction. This review, therefore, will provide a contemporary summary of the alterations currently known to occur in the skeletal muscles of both HFrEF and HFpEF, and provide some further directions that will be required if we want to improve our current understanding of this area. Recent findings: Skeletal muscle alterations are well documented for over 20 years in HFrEF, and during the recent years also data are presented that in HFpEF muscular alterations are present. Alterations are ranging from a shift in fiber type and capillarization to an induction of atrophy and modulation of mitochondrial energy supply. In general, the molecular alterations are more severe in the skeletal muscle of HFrEF when compared to HFpEF. Summary: The alterations occurring in the skeletal muscle at the molecular level may contribute to exercise intolerance in HFrEF and HFpEF. Nevertheless, the knowledge of changes in the skeletal muscle of HFpEF is still sparsely available and more studies in this HF cohort are clearly warranted. © 2017, Springer Science+Business Media, LLC.
引用
收藏
页码:489 / 497
页数:8
相关论文
共 104 条
[1]  
Benjamin E.J., Blaha M.J., Chiuve S.E., Cushman M., Das S.R., Deo R., Et al., Heart disease and stroke statistics—2017 update: a report from the American Heart Association, Circulation, 135, (2017)
[2]  
Arena R., Myers J., Aslam S.S., Varughese E.B., Peberdy M.A., Peak VO2 and VE/VCO2 slope in patients with heart failure: a prognostic comparison, Am Heart J, 147, pp. 354-360, (2004)
[3]  
Bhatia R.S., Tu J.V., Lee D.S., Austin P.C., Fang J., Haouzi A., Et al., Outcome of heart failure with preserved ejection fraction in a population-based study, New England Journal of Medicine, 355, pp. 260-269, (2006)
[4]  
Chioncel O., Lainscak M., Seferovic P.M., Anker S.D., Crespo-Leiro M.G., Harjola V.P., Et al., Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry, Eur J Heart Fail, (2017)
[5]  
The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis, European Heart Journal, 33, pp. 1750-1757, (2012)
[6]  
Massie B.M., Carson P.E., McMurray J.J., Komajda M., McKelvie R., Zile M.R., Et al., Irbesartan in patients with heart failure and preserved ejection fraction, New England Journal of Medicine, 359, pp. 2456-2467, (2008)
[7]  
Kitzman D.W., Hundley W.G., Brubaker P.H., Morgan T.M., Moore J.B., Stewart K.P., Et al., A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility, Circ Heart Fail, 3, pp. 477-485, (2010)
[8]  
Edelmann F., Wachter R., Schmidt A.G., Kraigher-Krainer E., Colantonio C., Kamke W., Et al., Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial, JAMA, 309, pp. 781-791, (2013)
[9]  
Kinugawa S., Tsutsui H., Ide T., Nakamura R., Arimura K., Egashira K., Et al., Positive inotropic effect of insulin-like growth factor-1 on normal and failing cardiac myocytes, Cardiovasc Res, 43, pp. 157-164, (1999)
[10]  
Cleland J.G.F., Tendera M., Adamus J., Freemantle N., Polonski L., Taylor J., The perindopril in elderly people with chronic heart failure (PEP-CHF) study, Eur Heart J, 27, pp. 2338-2345, (2006)